GoodRx (NASDAQ:GDRX) Shares Gap Down to $8.61

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $8.61, but opened at $7.16. GoodRx shares last traded at $6.54, with a volume of 587,417 shares.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on GDRX shares. Morgan Stanley increased their target price on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a report on Monday, June 10th. KeyCorp upgraded shares of GoodRx from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a research note on Wednesday, April 10th. TD Cowen lifted their price target on GoodRx from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 16th. Raymond James raised GoodRx from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a report on Thursday, May 16th. Finally, Royal Bank of Canada raised GoodRx from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $8.00 to $10.00 in a report on Thursday, May 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.32.

GoodRx Stock Performance

The company has a market cap of $2.65 billion, a price-to-earnings ratio of -685.00, a PEG ratio of 4.08 and a beta of 1.39. The stock has a 50 day simple moving average of $8.30 and a 200 day simple moving average of $7.38. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 1.02.

GoodRx (NASDAQ:GDRX) last released its earnings results on Thursday, May 9th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $197.88 million during the quarter, compared to the consensus estimate of $196.20 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. As a group, analysts predict that GoodRx Holdings, Inc. will post 0.17 EPS for the current year.

Hedge Funds Weigh In On GoodRx

Large investors have recently added to or reduced their stakes in the company. Cornercap Investment Counsel Inc. increased its position in GoodRx by 1.7% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock valued at $587,000 after acquiring an additional 1,266 shares during the period. American Century Companies Inc. acquired a new stake in shares of GoodRx in the second quarter worth $18,183,000. ClariVest Asset Management LLC boosted its position in GoodRx by 27.4% during the 2nd quarter. ClariVest Asset Management LLC now owns 195,722 shares of the company’s stock worth $1,527,000 after acquiring an additional 42,097 shares during the period. Picton Mahoney Asset Management lifted its position in GoodRx by 24.3% in the 2nd quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock worth $4,736,000 after buying an additional 118,703 shares in the last quarter. Finally, Legato Capital Management LLC purchased a new stake in shares of GoodRx during the second quarter worth $805,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.